Your browser doesn't support javascript.
loading
Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
Chen, Yu-Hong; Zhang, Xian; Cheng, Yi-Fei; Chen, Huan; Mo, Xiao-Dong; Yan, Chen-Hua; Chen, Yao; Han, Wei; Sun, Yu-Qian; Wang, Yu; Zhang, Xiao-Hui; Xu, Lan-Ping; Liu, Kai-Yan; Yang, Junfang; Zhang, Jianping; Zhang, Gai-Ling; Shi, Yanze; Su, Yun-Chao; Li, Wen-Qian; Xu, Li; Song, Dan; Zhang, Min; Lu, Peihua; Huang, Xiao-Jun.
Afiliación
  • Chen YH; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Zhang X; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Cheng YF; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Chen H; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Mo XD; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Yan CH; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Chen Y; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Han W; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Sun YQ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Wang Y; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Zhang XH; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Xu LP; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Liu KY; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Yang J; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Zhang J; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Zhang GL; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Shi Y; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Su YC; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Li WQ; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Xu L; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Song D; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Zhang M; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Lu P; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Huang XJ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. Electronic address: xjhrm@medmail.com.cn.
Cytotherapy ; 22(12): 755-761, 2020 12.
Article en En | MEDLINE | ID: mdl-32861622
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptores de Antígenos de Linfocitos T / Inmunoterapia Adoptiva / Trasplante de Células Madre Hematopoyéticas / Leucemia-Linfoma Linfoblástico de Células Precursoras Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Cytotherapy Asunto de la revista: TERAPEUTICA Año: 2020 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptores de Antígenos de Linfocitos T / Inmunoterapia Adoptiva / Trasplante de Células Madre Hematopoyéticas / Leucemia-Linfoma Linfoblástico de Células Precursoras Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Cytotherapy Asunto de la revista: TERAPEUTICA Año: 2020 Tipo del documento: Article País de afiliación: China